# LLY Investment Thesis (Updated 2025-10-01)

## Snapshot
- **Theme Alignment:** GLP-1 obesity/diabetes leadership, pipeline breadth, consumer channel expansion.
- **Portfolio Role:** Defensive growth with secular health trend exposure.
- **Scorecard:** Fundamentals 35/40, Technicals 17/25, Management 14/15, Risk 7/10, Sentiment 7/10.

## Thesis Pillars
1. **GLP-1 Market Leadership:** Zepbound/Mounjaro remain category leaders, with manufacturing expansions supporting double-digit volume growth.
2. **DTC Channel Expansion:** Direct-to-consumer efforts improve patient access and adherence, bolstering brand loyalty.
3. **Pipeline Diversification:** Obesity pill (orforglipron) data despite recent miss still indicates strong tolerability; broader pipeline (Alzheimer's, oncology) provides optionality.[1]

## Catalysts & Timeline
- **Q3 2025 Earnings (Nov):** Monitor obesity franchise revenue run-rate, capacity updates.
- **Regulatory Milestones:** FDA decisions on oral GLP-1 formulations and new indications.
- **Manufacturing Updates:** Progress on additional plants (NC, Indiana) to alleviate supply constraints.

## Key Metrics to Monitor
- GLP-1 script growth (>45% y/y), gross margin trajectory (>81%), R&D spend efficiency.
- Supply chain cadence, international reimbursement wins.

## Technical & Positioning
- Shares consolidating near ; support at 50d EMA (~).
- Accumulate on dips with stop below ; maintain 3% core position.

## Risk Factors
- Competitive pressure from Novo Nordisk oral GLP-1 and biosimilars mid-term.
- Manufacturing hiccups leading to supply constraints.
- Pricing/reimbursement pressures as payers manage obesity spend.

## Footnotes
[1]: BioPharma Dive, "Lilly shares fall as obesity pill misses expectations in key trial," 2025-08-08.
